Clinical Trials
13 trialsNCT01947023 2026-05-14
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01711658 2023-10-17
TRYHARD
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01044433 2020-03-19
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00498953 2018-07-09
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT00095563 2017-04-18
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
National Cancer Institute (NCI)
Phase 2 Completed
NCT00490061 2017-03-06
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Stanford University
Phase 2 Terminated
NCT00387127 2015-06-25
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00114283 2015-04-15
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00424255 2014-07-18
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
GlaxoSmithKline
Phase 3 Completed
NCT00098631 2014-01-07
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01184482 2013-10-31
TYKERB-ITUX 1
Georgetown University
Phase 1 Completed
NCT00371566 2010-04-06
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
GlaxoSmithKline
Phase 2 Completed